Cradle — AI Protein-Design SaaS ($73M Series B)
organizationAI & Compute
Designer proteins, sold like a software subscription.
Who they are
Cradle, a Zurich/Netherlands biotech.
What they do
It lets drug and industrial companies design proteins with AI without building their own labs or compute. It raised $73 million, passing $100 million total.
How it works
AI protein-design delivered as a cloud service — point, click, get a sequence.
Why it matters
Shows how the same money funds both the deep tools and the layer that resells them — ordinary investing, not a secret plan.
The engine's record — word for word
**In plain terms:** the commercial abstraction layer of generative biology — AI protein engineering sold as software so any pharma or industrial client can design proteins without owning the compute. Zurich/Netherlands-based Cradle raised $73 million in a Series B led by IVP (Index Ventures and Kindred Capital continuing), bringing total funding over $100 million[1]. Engine placement: a receipt for the funding-seam reading — the same venture ecosystem that funds foundational design tools (arc_institute_evo2) also funds the layer that abstracts and resells them; ordinary portfolio breadth, not a covert decision layer. Commercial layer of nucleic_acid_compiler. Held; name no holder.
Follow the trail
Walk this on the live map →